Lung Cancer News

Amivantamab-vmjw — with or without the addition of lazertinib — improved PFS versus chemotherapy alone in patients with EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

National Comprehensive Cancer Network’s Oncology Research Program awarded three grants to support research into small cell lung cancer.

Adjuvant therapy with alectinib prolonged DFS compared with platinum-based chemotherapy for certain patients with lung cancer, according to the agent’s manufacturer.

Assessment of body composition measurements on lung screening low-dose CT scans revealed patients at high risk for mortality due to lung cancer, cardiovascular disease and all causes, according to results published in Radiology.

Stereotactic ablative radiotherapy with immunotherapy significantly improvement EFS among patients with early-stage, treatment-naive or lung parenchymal recurrent node-negative non-small cell lung cancer, according to study results.

Researchers have developed a method to predict which individuals are at higher risk for lung cancer-related mortality.

Divarasib induced durable clinical responses among patients with KRAS G12C-positive solid tumors, according to study findings published in The New England Journal of Medicine.

Selpercatinib extended PFS compared with a PD-1 inhibitor-chemotherapy combination for certain adults with advanced non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

Tarlatamab exhibited activity among patients with relapsed or refractory small cell lung cancer, according to the agent’s manufacturer.

The FDA granted regular approval to pralsetinib for treatment of certain patients with non-small cell lung cancer.